Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

Bibliography

• LongstrethGF, ThompsonWG, CheyWD, et al.Functional bowel disorders. Gastroenterology2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• LovellRM, FordAC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol2012;10:712-21. e4
   PubMed Web of Science ®Google Scholar
• CamilleriM. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil2005;17:311-16
   PubMed Web of Science ®Google Scholar
• CamilleriM. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med2012;367:1626-35
   PubMed Web of Science ®Google Scholar
• OddssonE, Rask-MadsenJ, KragE. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol1978;13:409-16
   Web of Science ®Google Scholar
• DelvauxM, LouvelD, MametJP, et al.Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharm Ther1998;12:849-55
   PubMed Web of Science ®Google Scholar
• ViramontesBE, CamilleriM, McKinzieS, et al.Gender related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol2001;92:2671-6
   Google Scholar
• CamilleriM, MayerEA, DrossmanDA, et al.Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3-receptor antagonist. Aliment Pharmacol Ther1999;13:1149-59
   PubMed Web of Science ®Google Scholar
• CamilleriM, NorthcuttAR, KongS, et al.Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet2000;355:1035-40
   PubMed Web of Science ®Google Scholar
• JonesRH, HoltmannG, RodrigoL, et al.Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther1999;13:1419-27
   PubMed Web of Science ®Google Scholar
• ChangL, AmeenVZ, DukesGE, et al.A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol2005;100:115-23
   PubMed Web of Science ®Google Scholar
• AndresenV, MontoriVM, KellerJ, et al.Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol2008;6:545-55
   PubMed Web of Science ®Google Scholar
• ChangL, CheyWD, HarrisL, et al.Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol2006;101:1069-79
   PubMed Web of Science ®Google Scholar
• ChangL, TongK, AmeenV. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol2010;105:866-75
   PubMed Web of Science ®Google Scholar
• CremoniniF, NicandroJP, AtkinsonV, et al.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther2012;36:437-48
   PubMed Web of Science ®Google Scholar
• VassalloM, CamilleriM, PhillipsSF, et al.Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology1992;102:102-8
   PubMed Web of Science ®Google Scholar
• CamilleriM, McKinzieS, BusciglioI, et al.Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol2008;6:772-81
   PubMed Web of Science ®Google Scholar
• CannPA, ReadNW, HoldsworthCD, et al.Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci1984;29:239-47
   PubMed Web of Science ®Google Scholar
• AwoutersF, MegensA, VerlindenM, et al.Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci1993;38:977-95
   PubMed Web of Science ®Google Scholar
• GattusoJM, KammMA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf1994;10:47-65
   PubMed Web of Science ®Google Scholar
• PenfoldD, VolansGN. Overdose from Lomotil. Br Med J1977;2:1401-2
   PubMedGoogle Scholar
• ReadM, ReadNW, BarberDC, et al.Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci1982;27:807-14
   PubMed Web of Science ®Google Scholar
• LavöB, StenstamM, NielsenAL. Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study. Scand J Gastroenterol1987;130:77-80
   Google Scholar
• EfskindPS, BernklevT, VatnMH. A double-blind, placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol1996;31:463-8
   PubMed Web of Science ®Google Scholar
• ThaysenEH, PedersenL. Idiopathic bile salt catharsis. Gut1976;17:965-70
   PubMed Web of Science ®Google Scholar
• WedlakeL, A'HernR, RussellD, et al.Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther2009;30:707-17
   PubMed Web of Science ®Google Scholar
• WongBS, CamilleriM, CarlsonP, et al.Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol2012;10:1009-15. e3
   PubMed Web of Science ®Google Scholar
• SciarrettaG, FagioliG, FumoA, et al.75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut1987;28:970-5
   PubMed Web of Science ®Google Scholar
• BrydonWG, NyhlinH, EastwoodMA, et al.Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol1996;8:117-23
   PubMed Web of Science ®Google Scholar
• CamilleriM, PratherCM. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med1992;116:1001-8
   PubMed Web of Science ®Google Scholar
• Odunsi-ShiyanbadeST, CamilleriM, McKinzieS, et al.Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol2010;8:159-65
   PubMed Web of Science ®Google Scholar
• WongBS, CamilleriM, CarlsonPJ, et al.Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci2012;57:1222-6
   PubMed Web of Science ®Google Scholar
• HeefnerJD, WilderRM, WilsonJD. Irritable colon and depression. Psychosomatics1978;19:540-7
   PubMed Web of Science ®Google Scholar
• HislopIG. Psychological significance of the irritable colon syndrome. Gut1971;12:452-7
   PubMed Web of Science ®Google Scholar
• Lancaster-SmithMJ, ProutBJ, PintoT, et al.Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand1982;66:33-41
   PubMed Web of Science ®Google Scholar
• GreenbaumDS, MayleJE, VanegerenLE, et al.The effects of desipramine on IBS compared with atropine and placebo. Dig Dis Sci1987;32:257-66
   PubMed Web of Science ®Google Scholar
• MyrenJ, LovlandB, LarssenS-E, et al.A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol1984;19:835-43
   PubMed Web of Science ®Google Scholar
• RitchieJA, TrueloveSC. Comparison of various treatments for irritable bowel syndrome. Br Med J1980;281:1317-19
   PubMed Web of Science ®Google Scholar
• VahediH, MeratS, MomtahenS, et al.Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther2008;27:678-84
   PubMed Web of Science ®Google Scholar
• DrossmanDA, TonerBB, WhiteheadWE, et al.Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology2003;125:19-31
   PubMed Web of Science ®Google Scholar
• RuepertL, QuarteroAO, de WitNJ, et al.Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev2011;8):CD003460
   Google Scholar
• FordAC, TalleyNJ, SchoenfeldPS, et al.Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut2009;58:367-78
   PubMed Web of Science ®Google Scholar
• MasandPS, GuptaS, SchwartzTL, et al.Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?Psychosomatics2002;43:451-5
   PubMedGoogle Scholar
• FriedrichM, GradySE, WallGC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther2010;32:1221-33
   PubMedGoogle Scholar
• MoayyediP, FordAC, TalleyNJ, et al.The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut2010;59:325-32
   PubMed Web of Science ®Google Scholar
• PimentelM, LemboA, CheyWD, et al.Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med2011;364:22-32
   PubMed Web of Science ®Google Scholar
• MeneesSB, ManeerattannapornM, KimHM, CheyWD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol2012;107:28-35
   PubMed Web of Science ®Google Scholar
• ÖhmanL, SimrénM. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol2010;7:163-73
   PubMed Web of Science ®Google Scholar
• LoboB, VicarioM, MartinezC, et al.Clinical benefit in IBS after disodium cromoglycate involves mast cell-mediated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa. Gastroenterology2009;136(Suppl 1):156
   Google Scholar
• LoboB, VicarioM, MartinezC, et al.Clinical improvement in IBS after disodium cromoglycate involves mast cell-mediated toll-like receptor signaling downregulation. Gastroenterology2011;140(Suppl 1):499-500
   Google Scholar
• LeriO, TubiliS, De RosaFG, et al.Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammopharmacology1997;5:153-8
   PubMedGoogle Scholar
• GayJ, RessayreL, Garcia-VillarR, et al.Alteration of CCK-induced satiety in post-Nippostrongylus brasiliensis-infected rats. Brain Behav Immun2003;17:35-42
   PubMedGoogle Scholar
• KlookerTK, BraakB, KoopmanKE, et al.The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut2010;59:1213-21
   PubMed Web of Science ®Google Scholar
• CorinaldesiR, StanghelliniV, CremonC, et al.Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther2009;30:245-52
   PubMed Web of Science ®Google Scholar
• AndrewsCN, GriffithsTA, KaufmanJ, et al.Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther2011;34:374-83
   PubMed Web of Science ®Google Scholar
• DorofeyevAE, KiriyanEA, VasilenkoIV, et al.Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol2011;4:141-53
   PubMedGoogle Scholar
• TutejaAK, FangJC, Al-SuqiM, et al.Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome–a pilot study. Scand J Gastroenterol2012;47:1159-64
   PubMed Web of Science ®Google Scholar
• AtkinsonW, LockhartS, WhorwellPJ, et al.Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology2006;130:34-43
   PubMed Web of Science ®Google Scholar
• FaureC, PateyN, GauthierC, et al.Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology2010;139:249-58
   PubMed Web of Science ®Google Scholar
• HoffmanJM, TylerK, MacEachernSJ, et al.Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology2012;142:844-54
   PubMed Web of Science ®Google Scholar
• FreimanJ, JacksonJ, FrazierKS, et al.LX1031: inhibition of 5-HT synthesis as a new target in the management of irritable bowel syndrome (IBS). Neurogastroenterol Motil2009;21:250
   Google Scholar
• BrownPM, DrossmanDA, WoodAJ, et al.The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology2011;141:507-16
   PubMed Web of Science ®Google Scholar
• HirataT, FunatsuT, KetoY, et al.Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology2007;15:5-9
   PubMedGoogle Scholar
• HirataT, KetoY, NakataM, et al.Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil2008;20:557-65
   PubMed Web of Science ®Google Scholar
• MatsuedaK, HarasawaS, HongoM, et al.A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion2008;77:225-35
   PubMed Web of Science ®Google Scholar
• MatsuedaK, HarasawaS, HongoM, et al.A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol2008;43:1202-11
   PubMed Web of Science ®Google Scholar
• LeeKJ, KimNY, KwonJK, et al.Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil2011;23:1098-104
   PubMed Web of Science ®Google Scholar
• AndersonK, FischerL. Prevention of GI absorption of bacterial toxins: an in vitro evaluation of the potential for prophylactic use of a novel oral adsorbent (AST-120). Gastroenterology2008;134(Suppl 1):A-675
   Google Scholar
• AndersonK, TomiyamaS, NittaT. A novel, engineered carbon microsphere product for use in chronic inflammatory bowel disease and liver dysfunction. Gastroenterology2008;134(Suppl 1):A-675
   Google Scholar
• TackJF, MinerPBJr, FischerL, et al.Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther2011;34:868-77
   PubMed Web of Science ®Google Scholar
• LeventerSM, KucharikRF, KeoghJC, et al.The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. Am J Gastroenterol2004;99(Suppl 5):S279
   Google Scholar
• LeventerSM, RaudibaughK, FrissoraCL, et al.Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther2008;27:197-206
   PubMed Web of Science ®Google Scholar
• DelvauxM, BeckA, JacobJ, et al.Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther2004;20:237-46
   PubMed Web of Science ®Google Scholar
• Delgado-ArosS, ChialHJ, CamilleriM, et al.Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol2003;284:G558-66
   PubMed Web of Science ®Google Scholar
• MangelAW, BornsteinJD, HammLR, et al.Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther2008;28:239-49
   PubMed Web of Science ®Google Scholar
• SpiegelB, StricklandA, NaliboffBD, et al.Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol2008;103:2536-44
   PubMedGoogle Scholar
• TrentacostiAM, HeR, BurkeLB, et al.Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol2010;105:731-5
   PubMedGoogle Scholar
• DegenLP, PhillipsSF. How well does stool form reflect colonic transit?Gut1996;39:109-13
   PubMed Web of Science ®Google Scholar
• CamilleriM. Pharmacology of the new treatments for lower gastrointestinal disorders and irritable bowel syndrome.Clin Pharmacol Ther2012;91:44-59
   PubMed Web of Science ®Google Scholar